Dr. E. Martinez and colleagues from Barcelona, Spain, reported on 80 patients who received ddI once a day, plus D4T 40 mg bid, with or without saquinavir or indinavir. The mean baseline CD4 count was 178 cells/mm3, and the mean plasma viral load was 4.9 logs. Less than 10% of the patients complained about gi side effects or had to withdraw from the study. CD4 counts increased a mean of 86 cells/mm3 and viral load decreased 1.9 logs at 3 months. 43% of patients had peripheral viral loads below 200 copies/ml (all of these were taking a protease inhibitor). The data suggest that daily dosing of ddI is consistent with a good clinical response to combination chemotherapy and deserves further study.